Digital health companies should stay away from FDA in 2021

Digital health companies should stay away from FDA in 2021

As the agency's workload swells with the weight of a public health emergency, digital health companies on a timeline should consider whether their products truly warrant a regulatory submission, writes Epstein Becker & Green's Bradley Merrill Thompson.


Deploy this technology today



Next Article

  • Our Favourite Digital Health Articles Of 2020

    Our Favourite Digital Health Articles Of 2020

    Yes, it’s THAT time of the year and it’s always good to look back at the year – even to this one. For it’s easy to say 2020 was disastrous, but there were many aspects that bring hope for the future …

    Posted Dec 22, 2020digital health

Did you find this useful?

Medigy Innovation Network

Connecting innovation decision makers to authoritative information, institutions, people and insights.

Medigy Logo

The latest News, Insights & Events

Medigy accurately delivers healthcare and technology information, news and insight from around the world.

The best products, services & solutions

Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.


© 2024 Netspective Media LLC. All Rights Reserved.

Built on Mar 28, 2024 at 3:00am